JOHN KIRKWOOD to Lymphocytes, Tumor-Infiltrating
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Lymphocytes, Tumor-Infiltrating.
Connection Strength
1.062
-
Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
Score: 0.239
-
Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. Oncologist. 2024 Jul 05; 29(7):619-628.
Score: 0.161
-
Poorer survival outcomes in patients with multiple versus single primary melanoma. Cancer. 2022 06 01; 128(11):2098-2106.
Score: 0.137
-
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 08 20; 39(24):2656-2666.
Score: 0.129
-
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015 Apr 15; 75(8):1635-44.
Score: 0.084
-
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008 Mar 01; 180(5):2967-80.
Score: 0.052
-
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
Score: 0.041
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
Score: 0.041
-
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 12; 10(12).
Score: 0.036
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.032
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
Score: 0.030
-
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
Score: 0.030
-
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017 09 21; 2(18).
Score: 0.025
-
Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 1996 Sep 01; 25(1):71-81.
Score: 0.023